Literature DB >> 7771859

Achalasia and squamous cell carcinoma of the esophagus: analysis of 241 patients.

J M Streitz1, F H Ellis, S P Gibb, G M Heatley.   

Abstract

Achalasia of the esophagus is presumed by many to be a premalignant lesion leading to an increased risk of squamous cell carcinoma. There is disagreement, however, as to the precise risk of malignant degeneration and there is no consensus as to either the need for close surveillance of achalasia patients or the surveillance technique that should be employed. A review of the available literature on the subject has disclosed a wide range of reported cancer risks in achalasia patients, from zero to 33 times that of the normal population. Cancers, when discovered, are often unresectable and the median survival when they are resectable is low. A personal experience with 241 achalasia patients treated during the past quarter of a century disclosed that 9 had carcinoma, for a prevalence of 3.7%. Carcinoma developed in 3 of these 9 while they were under our observation. This translates into one cancer per 1,138 patient-years of follow-up, an incidence of 88 per 100,000 population, and a risk 14.5 times that of the age-adjusted and sex-adjusted general population. Because of the low postresection survival rate if treatment is delayed until carcinoma of the esophagus becomes symptomatic, closer surveillance of achalasia patients is recommended than has been the case. Because it seems unlikely that close endoscopic surveillance will prove to be cost-effective, periodic (every 2 to 3 years) blind brush biopsy warrants further study as a means of surveillance.

Entities:  

Mesh:

Year:  1995        PMID: 7771859     DOI: 10.1016/0003-4975(94)00997-l

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  31 in total

1.  SAGES guidelines for the surgical treatment of esophageal achalasia.

Authors:  Dimitrios Stefanidis; William Richardson; Timothy M Farrell; Geoffrey P Kohn; Vedra Augenstein; Robert D Fanelli
Journal:  Surg Endosc       Date:  2011-11-02       Impact factor: 4.584

Review 2.  Achalasia--a disease of unknown cause that is often diagnosed too late.

Authors:  Ines Gockel; Michaela Müller; Johannes Schumacher
Journal:  Dtsch Arztebl Int       Date:  2012-03-23       Impact factor: 5.594

Review 3.  Regenerative Medicine Strategies for Esophageal Repair.

Authors:  Ricardo Londono; Stephen F Badylak
Journal:  Tissue Eng Part B Rev       Date:  2015-04-30       Impact factor: 6.389

4.  Achalasia: a risk factor that must not be forgotten for esophageal squamous cell carcinoma.

Authors:  Shareni Ríos-Galvez; Arturo Meixueiro-Daza; Jose Maria Remes-Troche
Journal:  BMJ Case Rep       Date:  2015-01-06

Review 5.  Peroral endoscopic myotomy: an evolving treatment for achalasia.

Authors:  Robert Bechara; Haruo Ikeda; Haruhiro Inoue
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-02       Impact factor: 46.802

6.  Effects of estrogen on esophageal function through regulation of Ca2+-related proteins.

Authors:  Kipung Kim; Dongoh Lee; Changhwan Ahn; Hee Young Kang; Beum-Soo An; Yeon Hee Seong; Eui-Bae Jeung
Journal:  J Gastroenterol       Date:  2017-01-11       Impact factor: 7.527

7.  Endoscopic approach to achalasia.

Authors:  Michaela Müller; Alexander J Eckardt; Till Wehrmann
Journal:  World J Gastrointest Endosc       Date:  2013-08-16

8.  Lugol chromoendoscopy combined with brush cytology in patients at risk for esophageal squamous cell carcinoma.

Authors:  D Boller; P Spieler; R Schoenegg; J Neuweiler; D Kradolfer; R Studer; R Grossenbacher; U Zuercher; C Meyenberger; J Borovicka
Journal:  Surg Endosc       Date:  2009-05-15       Impact factor: 4.584

Review 9.  Are idiopathic and Chagasic achalasia two different diseases?

Authors:  Fernando A M Herbella; Daniel R C F Oliveira; Jose C Del Grande
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

Review 10.  Environmental causes of esophageal cancer.

Authors:  Farin Kamangar; Wong-Ho Chow; Christian C Abnet; Sanford M Dawsey
Journal:  Gastroenterol Clin North Am       Date:  2009-03       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.